May 2026
1. XU Y, Malek ND, Chang AR, Echouffo-Tcheugui JB, et al
   Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.
   Nat Med. 2026;32:1682-1685.
   

   >> Share

   
   January 2026
2. TEERAWATTANANON Y, Chavarina KK, Phannajit J, Sutawong J, et al
   Nature Medicine Commission on dialysis policy in low- and middle-income countries.
   Nat Med. 2026;32:58-71.
   

   >> Share

   
   
3. TEERAWATTANANON Y, Chavarina KK, Phannajit J, Sutawong J, et al
   The path to safe, equitable and sustainable dialysis provision for people with chronic kidney disease.
   Nat Med. 2026;32:44-46.
   

   >> Share

   
   May 2025
4. SUN Z, Yi Z, Wei C, Wang W, et al
   LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.
   Nat Med. 2025;31:1677-1687.
   

   >> Share

   
   January 2025
5. TEERAWATTANANON Y, Chavarina KK, Phannajit J, Sutawong J, et al
   The Access to Dialysis in Low- and Middle-Income Countries Commission: lessons for universal health coverage.
   Nat Med. 2025;31:19-21.
   

   >> Share

   
   October 2024
6. VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al
   Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
   Nat Med. 2024 Oct 28. doi: 10.1038/s41591-024-03372.
   

   >> Share

   
   
7. APPERLOO EM, Gorriz JL, Soler MJ, Cigarran Guldris S, et al
   Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
   Nat Med. 2024 Oct 25. doi: 10.1038/s41591-024-03327.
   

   >> Share

   
   September 2024
8. HOBBS FDR, McManus RJ, Taylor CJ, Jones NR, et al
   Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
   Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03263.
   

   >> Share

   
   
9. VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al
   Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes.
   Nat Med. 2024 Sep 1. doi: 10.1038/s41591-024-03264.
   

   >> Share

   
   July 2024
10. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
    Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03156.
    

    >> Share

    
    June 2024
11. MANN JFE, Rossing P, Bakris G, Belmar N, et al
    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
    Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133.
    

    >> Share

    
    May 2024
12. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
    IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
    Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03043.
    

    >> Share

    
    
13. KONDO T, Jhund PS, Gasparyan SB, Yang M, et al
    A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.
    Nat Med. 2024;30:1432-1439.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share